GS1-144 clinical trials
How each study uses GS1-144 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GS1-144 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2024 | 3 |
| 2026 | 3 |
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test GS1-144.
- Jan 2027GS1-144 in Participants With Hepatic Impairment and Healthy FemalePhase 1 · Changchun GeneScience Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses GS1-144 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- GS1-144 in Participants With Hepatic Impairment and Healthy FemaleNot yet recruitingPhase 1Changchun GeneScience Pharmaceutical Co., Ltd.NCT07491289Written as GS1-144 tablet
- To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets .CompletedPhase 1Changchun GeneScience Pharmaceutical Co., Ltd.NCT07534176Written as GS1-144 tablets
- A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Female ParticipantsActive, not recruitingPhase 1Changchun GeneScience Pharmaceutical Co., Ltd.NCT07537231Written as [14C]GS1-144
- Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.CompletedPhase 2Changchun GeneScience Pharmaceutical Co., Ltd.NCT06726850Written as GS1-144
- A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese PopulationCompletedPhase 1Changchun GeneScience Pharmaceutical Co., Ltd.NCT06385158Written as GS1-144 tablet
- A Study to Assess Safety and Tolerability of GS1-144 in Healthy VolunteersCompletedPhase 1Changchun GeneScience Pharmaceutical Co., Ltd.NCT06204250Written as GS1-144